- Home
- EAF vs CBIO Comparison
EAF vs CBIO Comparison
Compare EAF & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- CBIO
- Stock Information
- Founded
- EAF 1886
- CBIO 2003
- Country
- EAF United States
- CBIO United States
- Employees
- EAF N/A
- CBIO N/A
- Industry
- EAF Industrial Machinery/Components
- CBIO
- Sector
- EAF Energy
- CBIO
- Exchange
- EAF Nasdaq
- CBIO Nasdaq
- Market Cap
- EAF 265.9M
- CBIO 308.0M
- IPO Year
- EAF 1995
- CBIO N/A
- Fundamental
- Price
- EAF $1.27
- CBIO $13.79
- Analyst Decision
- EAF Hold
- CBIO Strong Buy
- Analyst Count
- EAF 6
- CBIO 4
- Target Price
- EAF $1.70
- CBIO $25.50
- AVG Volume (30 Days)
- EAF 2.3M
- CBIO 92.1K
- Earning Date
- EAF 07-25-2025
- CBIO 07-31-2025
- Dividend Yield
- EAF N/A
- CBIO N/A
- EPS Growth
- EAF N/A
- CBIO N/A
- EPS
- EAF N/A
- CBIO N/A
- Revenue
- EAF $508,550,000.00
- CBIO N/A
- Revenue This Year
- EAF N/A
- CBIO N/A
- Revenue Next Year
- EAF $26.79
- CBIO N/A
- P/E Ratio
- EAF N/A
- CBIO N/A
- Revenue Growth
- EAF N/A
- CBIO N/A
- 52 Week Low
- EAF $0.55
- CBIO $10.83
- 52 Week High
- EAF $2.53
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- EAF 51.00
- CBIO N/A
- Support Level
- EAF $1.16
- CBIO N/A
- Resistance Level
- EAF $1.39
- CBIO N/A
- Average True Range (ATR)
- EAF 0.14
- CBIO 0.00
- MACD
- EAF -0.01
- CBIO 0.00
- Stochastic Oscillator
- EAF 26.27
- CBIO 0.00
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.